Center-Authored Papers

Filters: Author is Parnes, Howard  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2008
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia SM, Goodman P, Parnes H, Coltman CA.  2008.  The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.. The Journal of urology. 180(2):544-7. Abstract
2010
Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen CM, Kristal AR, Lucia S, Wang Q, Kappil M, Thompson I et al..  2010.  Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.. Cancer prevention research (Philadelphia, Pa.). 3(4):478-83. Abstract
2014
Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch GH, Hwang S, Berry DA, Kinzler KW, Black WC et al..  2014.  Addressing overdiagnosis and overtreatment in cancer: a prescription for change.. The lancet oncology. 15(6):e234-42. Abstract
Aged
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia SM, Goodman P, Parnes H, Coltman CA.  2008.  The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.. The Journal of urology. 180(2):544-7. Abstract
Aged, 80 and over
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia SM, Goodman P, Parnes H, Coltman CA.  2008.  The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.. The Journal of urology. 180(2):544-7. Abstract
Biopsy, Needle
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia SM, Goodman P, Parnes H, Coltman CA.  2008.  The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.. The Journal of urology. 180(2):544-7. Abstract
Case-Control Studies
Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen CM, Kristal AR, Lucia S, Wang Q, Kappil M, Thompson I et al..  2010.  Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.. Cancer prevention research (Philadelphia, Pa.). 3(4):478-83. Abstract
Center-Authored Paper
Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch GH, Hwang S, Berry DA, Kinzler KW, Black WC et al..  2014.  Addressing overdiagnosis and overtreatment in cancer: a prescription for change.. The lancet oncology. 15(6):e234-42. Abstract
Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen CM, Kristal AR, Lucia S, Wang Q, Kappil M, Thompson I et al..  2010.  Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.. Cancer prevention research (Philadelphia, Pa.). 3(4):478-83. Abstract
Clinical Research Division
Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch GH, Hwang S, Berry DA, Kinzler KW, Black WC et al..  2014.  Addressing overdiagnosis and overtreatment in cancer: a prescription for change.. The lancet oncology. 15(6):e234-42. Abstract
Confidence Intervals
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia SM, Goodman P, Parnes H, Coltman CA.  2008.  The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.. The Journal of urology. 180(2):544-7. Abstract
Digital Rectal Examination
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia SM, Goodman P, Parnes H, Coltman CA.  2008.  The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.. The Journal of urology. 180(2):544-7. Abstract
Double-Blind Method
Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen CM, Kristal AR, Lucia S, Wang Q, Kappil M, Thompson I et al..  2010.  Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.. Cancer prevention research (Philadelphia, Pa.). 3(4):478-83. Abstract
Enzyme Inhibitors
Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen CM, Kristal AR, Lucia S, Wang Q, Kappil M, Thompson I et al..  2010.  Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.. Cancer prevention research (Philadelphia, Pa.). 3(4):478-83. Abstract
Enzyme-Linked Immunosorbent Assay
Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen CM, Kristal AR, Lucia S, Wang Q, Kappil M, Thompson I et al..  2010.  Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.. Cancer prevention research (Philadelphia, Pa.). 3(4):478-83. Abstract
Finasteride
Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen CM, Kristal AR, Lucia S, Wang Q, Kappil M, Thompson I et al..  2010.  Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.. Cancer prevention research (Philadelphia, Pa.). 3(4):478-83. Abstract
Human Biology Division
Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch GH, Hwang S, Berry DA, Kinzler KW, Black WC et al..  2014.  Addressing overdiagnosis and overtreatment in cancer: a prescription for change.. The lancet oncology. 15(6):e234-42. Abstract
Humans
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia SM, Goodman P, Parnes H, Coltman CA.  2008.  The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.. The Journal of urology. 180(2):544-7. Abstract
Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen CM, Kristal AR, Lucia S, Wang Q, Kappil M, Thompson I et al..  2010.  Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.. Cancer prevention research (Philadelphia, Pa.). 3(4):478-83. Abstract
Immunohistochemistry
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia SM, Goodman P, Parnes H, Coltman CA.  2008.  The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.. The Journal of urology. 180(2):544-7. Abstract
Male
Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen CM, Kristal AR, Lucia S, Wang Q, Kappil M, Thompson I et al..  2010.  Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.. Cancer prevention research (Philadelphia, Pa.). 3(4):478-83. Abstract
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia SM, Goodman P, Parnes H, Coltman CA.  2008.  The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.. The Journal of urology. 180(2):544-7. Abstract
Mass Screening
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia SM, Goodman P, Parnes H, Coltman CA.  2008.  The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.. The Journal of urology. 180(2):544-7. Abstract
May 2014
Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch GH, Hwang S, Berry DA, Kinzler KW, Black WC et al..  2014.  Addressing overdiagnosis and overtreatment in cancer: a prescription for change.. The lancet oncology. 15(6):e234-42. Abstract
Middle Aged
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia SM, Goodman P, Parnes H, Coltman CA.  2008.  The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.. The Journal of urology. 180(2):544-7. Abstract